Der Pharma Chemica
Journal for Medicinal Chemistry, Pharmaceutical Chemistry, Pharmaceutical Sciences and Computational Chemistry

Abstract

Dolutegravir, Second Generation Integrase Inhibitor: A New Hope for HIV Patients

Author(s): Geeta Yadav, Piyush Kumar

Undeterred efforts have been made and will be made in future to make it possible for HIV-infected individuals to achieve the goals of virologic suppression and one more addition to this rigorous exercise is dolutegravir drug. It is a recent integrase inhibitor approved by the United States of Food and Drug Administration (USFDA) for use in the treatment-naïve and treatment-experienced HIV-infected patients. This article has reviewed all the aspects of drug including the structural and functional analyses, in vitro activity, pharmacokinetics, drug-drug interactions, MOA, metabolism, excretion, dosing/adverse effects and resistance profile. Dolutegravir is a potent and well tolerated antiretroviral agent that may play an important role in the treatment of patients harboring resistance to other antiretrovirals. Some new combinations of drug with other antiretrovirals are also in pipeline which may hope to increase the immunologic response of the HIV patients.


Full-Text PDF